Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Autosomal dominant retinitis pigmentosa Indication Strategy Report 2026: RHO, Trials and Deals
23 July 2026
2026 Autosomal dominant retinitis pigmentosa strategy: epidemiology, RHO biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Autosomal recessive retinitis pigmentosa Indication Strategy Report 2026: PDE6B, Trials and Deals
23 July 2026
2026 Autosomal recessive retinitis pigmentosa strategy: epidemiology, PDE6B biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pattern dystrophy Indication Strategy Report 2026: PRPH2, Trials and Deals
23 July 2026
2026 Pattern dystrophy strategy: epidemiology, PRPH2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Usher syndrome type 3 Indication Strategy Report 2026: CLRN1, Trials and Deals
23 July 2026
2026 Usher syndrome type 3 strategy: epidemiology, CLRN1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Usher syndrome type 2A Indication Strategy Report 2026: USH2A, Trials and Deals
23 July 2026
2026 Usher syndrome type 2A strategy: epidemiology, USH2A biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Achromatopsia type 3 Indication Strategy Report 2026: CNGB3, Trials and Deals
23 July 2026
2026 Achromatopsia type 3 strategy: epidemiology, CNGB3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Leber congenital amaurosis type 10 Indication Strategy Report 2026: CEP290, Trials and Deals
23 July 2026
2026 Leber congenital amaurosis type 10 strategy: epidemiology, CEP290 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital cataract Indication Strategy Report 2026: CRYAA, Trials and Deals
23 July 2026
2026 Congenital cataract strategy: epidemiology, CRYAA biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Achromatopsia type 2 Indication Strategy Report 2026: CNGA3, Trials and Deals
23 July 2026
2026 Achromatopsia type 2 strategy: epidemiology, CNGA3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Acanthamoeba keratitis Indication Strategy Report 2026: Acanthamoeba CYP51, Trials and Deals
23 July 2026
2026 Acanthamoeba keratitis strategy: epidemiology, Acanthamoeba CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Paracoccidioidomycosis Indication Strategy Report 2026: Paracoccidioides CYP51, Trials and Deals
23 July 2026
2026 Paracoccidioidomycosis strategy: epidemiology, Paracoccidioides CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Coccidioidomycosis Indication Strategy Report 2026: Coccidioides CYP51, Trials and Deals
23 July 2026
2026 Coccidioidomycosis strategy: epidemiology, Coccidioides CYP51 biology, clinical competition, recent deals, unmet need and market attractiveness.